Willem P. van Lawick

Fondateur chez

MedSciences Capital Management BV

Consumer Services

Health Technology

Finance

Profil

Willem P.
van Lawick is the founder of MedSciences Capital Management BV, where he holds the title of Investment Manager starting in 2000.
He is currently the Chairman of Organ Assist BV and PulseCath BV.
Dr. van Lawick received an MBA from INSEAD and a doctorate from the University of Leiden.

Postes actifs de Willem P. van Lawick

Sociétés	Poste	Début
MedSciences Capital Management BV MedSciences Capital Management BV Investment ManagersFinance MSCM's investment strategy focuses on early- to mid-stage life sciences firms. They look for ventures with robust innovations displaying significant value growth potential. They target firms in the Benelux region. They typically invest a maximum ranging between EUR 2.5 million and EUR 3 million. They consider higher levels of financing when associated with other professional providers of capital. The firm looks for investment criteria such as products addressing a substantial unmet medical need, products with a compelling competitive edge and benefiting from patent protection, experienced management to lead the firm through their development stage, and clarity and feasibility of their business model. MSCM concentrates on firms developing diagnostics, therapeutics, or medical devices for human use. They have invested in specific areas such as intra-ocular lenses for treatment of cataract and presbyopia, therapeutics to attenuate overreactions of the immune system, treatment options for terminally ill cancer patients, development of products for treatment of type II diabetes, adjuvants for prophylactic and therapeutic vaccines, molecular tests for monitoring toxic side effects of antiviral medication, development of therapeutics on the basis of RNA modulation, and development of periodontitis treatment. Key to MSCM's investment process is financial planning in order to create optimal exit opportunities. Their preferred investment time frame is approximately five years.	Fondateur	06/10/2000
PulseCath BV PulseCath BV Medical SpecialtiesHealth Technology Develops, manufactures and markets circulatory support systems	Président	31/08/2009
Organ Assist BV Organ Assist BV Medical SpecialtiesHealth Technology Develops a medical device for organ preservation	Président	-

Tous les postes actifs de Willem P. van Lawick

Formation de Willem P. van Lawick

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Willem P. van Lawick

Relations

Relations au 1er degré

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées	5
INSEAD INSEAD Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Leiden University of Leiden Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Organ Assist BV Organ Assist BV Medical SpecialtiesHealth Technology Develops a medical device for organ preservation	Health Technology
MedSciences Capital Management BV MedSciences Capital Management BV Investment ManagersFinance MSCM's investment strategy focuses on early- to mid-stage life sciences firms. They look for ventures with robust innovations displaying significant value growth potential. They target firms in the Benelux region. They typically invest a maximum ranging between EUR 2.5 million and EUR 3 million. They consider higher levels of financing when associated with other professional providers of capital. The firm looks for investment criteria such as products addressing a substantial unmet medical need, products with a compelling competitive edge and benefiting from patent protection, experienced management to lead the firm through their development stage, and clarity and feasibility of their business model. MSCM concentrates on firms developing diagnostics, therapeutics, or medical devices for human use. They have invested in specific areas such as intra-ocular lenses for treatment of cataract and presbyopia, therapeutics to attenuate overreactions of the immune system, treatment options for terminally ill cancer patients, development of products for treatment of type II diabetes, adjuvants for prophylactic and therapeutic vaccines, molecular tests for monitoring toxic side effects of antiviral medication, development of therapeutics on the basis of RNA modulation, and development of periodontitis treatment. Key to MSCM's investment process is financial planning in order to create optimal exit opportunities. Their preferred investment time frame is approximately five years.	Finance
PulseCath BV PulseCath BV Medical SpecialtiesHealth Technology Develops, manufactures and markets circulatory support systems	Health Technology